These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 21694467)
1. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa. von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467 [TBL] [Abstract][Full Text] [Related]
2. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152 [TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
4. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828 [TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754 [TBL] [Abstract][Full Text] [Related]
6. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793 [TBL] [Abstract][Full Text] [Related]
7. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829 [TBL] [Abstract][Full Text] [Related]
8. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844 [TBL] [Abstract][Full Text] [Related]
10. NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Menke V; van Zoest KP; Moons LM; Hansen B; Pot RG; Siersema PD; Kusters JG; Kuipers EJ Scand J Gastroenterol; 2012 Apr; 47(4):378-86. PubMed ID: 22243485 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482 [TBL] [Abstract][Full Text] [Related]
12. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Swami S; Kumble S; Triadafilopoulos G Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899 [TBL] [Abstract][Full Text] [Related]
13. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963 [TBL] [Abstract][Full Text] [Related]
14. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359 [TBL] [Abstract][Full Text] [Related]
15. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840 [TBL] [Abstract][Full Text] [Related]
16. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225 [TBL] [Abstract][Full Text] [Related]
17. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Burnat G; Rau T; Elshimi E; Hahn EG; Konturek PC Scand J Gastroenterol; 2007 Dec; 42(12):1460-5. PubMed ID: 17852856 [TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Yacoub L; Goldman H; Odze RD Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315 [TBL] [Abstract][Full Text] [Related]
19. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568 [TBL] [Abstract][Full Text] [Related]